Evidence map›Paper›PMID 39222177›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2025

Telomere transcripts act as tumor suppressor and are associated with favorable prognosis in colorectal cancer with low proliferating cell nuclear antigen expression.

Philip Kienzl, Abigail J Deloria, Monika Hunjadi, Juliane M Hadolt, Max-Felix Haering, Angrit Bothien, Doris Mejri, Medina Korkut-Demirbaş, Sandra Sampl, Gerhard Weber and 13 more

Abstract read
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Philip KienzlCenter for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, Vienna, A-1090, Austria.
Abigail J DeloriaCenter for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, Vienna, A-1090, Austria.
Monika HunjadiCenter for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, Vienna, A-1090, Austria.
Juliane M HadoltCenter for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, Vienna, A-1090, Austria.
Max-Felix HaeringCenter for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, Vienna, A-1090, Austria.
Angrit BothienCenter for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, Vienna, A-1090, Austria.
Doris MejriCenter for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, Vienna, A-1090, Austria.
Medina Korkut-DemirbaşCenter for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, Vienna, A-1090, Austria.
Sandra SamplCenter for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, Vienna, A-1090, Austria.
Gerhard WeberCenter for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, Vienna, A-1090, Austria.
Christine PirkerCenter for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, Vienna, A-1090, Austria.
Severin LaengleDepartment of Cardiac Surgery, Medical University of Vienna, Vienna, Austria.
Tamara BraunschmidDepartment of Surgery, Social Medical Center South, Kaiser Franz Josef Hospital, Vienna, Austria.
Eleni DragonaLaboratory of Genetics Center of Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Greece (BRFAA), Soranou Efesiou 4, Athens, 115 27, Greece.
Brigitte MarianCenter for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, Vienna, A-1090, Austria.
Sarantis GagosLaboratory of Genetics Center of Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Greece (BRFAA), Soranou Efesiou 4, Athens, 115 27, Greece.
Lingeng LuDepartment of Chronic Disease Epidemiology, Yale School of Public Health, School of Medicine, Yale Cancer Center, Yale University, New Haven, USA.
Jeremy D HensonPrince of Wales Clinical School, University of NSW, UNSW, Sydney, 2052, Australia.
Loretta M S LauChildren's Cancer Research Unit, The Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney, Westmead, 2145, Australia.
Roger R ReddelChildren's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, 2145, Australia.
Wolfgang MikulitsCenter for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, Vienna, A-1090, Austria.
Stefan StättnerDepartment of Surgery, Social Medical Center South, Kaiser Franz Josef Hospital, Vienna, Austria.
Klaus HolzmannCenter for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, Vienna, A-1090, Austria. klaus.holzmann@meduniwien.ac.at.ORCID http://orcid.org/0000-0003-4077-3377

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Telomeric repeat-containing RNAs (TERRA) and telomerase RNA component (TERC) regulate telomerase activity (TA) and thereby contribute to telomere homeostasis by influencing telomere length (TL) and the cell immortality hallmark of cancer cells. Additionally, the non-canonical functions of telomerase reverse transcriptase (TERT) and TERRA appear to be involved in the epithelial-mesenchymal transition (EMT), which is important for cancer progression. However, the relationship between TERRA and patient prognosis has not been fully characterized. In this small-scale study, 68 patients with colorectal cancer (CRC) were evaluated for correlations between telomere biology, proliferation, and EMT gene transcripts and disease outcome. The proliferating cell nuclear antigen (PCNA) and the epithelial splicing regulatory proteins 1 and 2 (ESRP1 and ESRP2) showed a positive correlation with TERRA, while TA and TERRA exhibited an inverse correlation. Consistent with previous findings, the present study revealed higher expression levels of TERT and TERC, and increased TA and TL in CRC tumor tissue compared to adjacent non-tumor tissue. In contrast, lower expression levels of TERRA were observed in tumor tissue. Patients with high TERRA expression and low PCNA levels exhibited favorable overall survival rates compared to individuals with the inverse pattern. Furthermore, TERRA suppressed CRC tumor growth in severe combined immunodeficiency disease (SCID) mice. In conclusion, our study extends previously published research on TERRA suggesting its potential therapeutic role in telomerase-positive CRC.

Indexed as

Colorectal NeoplasmsProliferating Cell Nuclear AntigenTelomereAgedAnimalsCell Line, TumorCell ProliferationEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMiddle AgedPrognosisRNAProliferating Cell Nuclear AntigenRNATelomerasetelomerase RNAColorectal cancer survivalCorrelation studyTelomere and proliferation parametersTumor progression

Identifiers

PMID39222177
PMCPMC11850466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.